PolarityTE Inc.

PolarityTE — Investor Presentation (March 2017)

54 slides from PolarityTE's investor presentation, Mar 13, 2017

  1. Slide 1: Forward Looking Statements

    FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements and projections. The company makes no express or implied representation or warranty as to the completeness of this information or, in the case of projections, as to their attainability or the accuracy and completeness o

  2. Slide 2: Opportunity, Strategy, Pipeline, Partnering, Team

    OPPORTUNITY Early growth stage regenerative medicine company with a platform technology able to create y functional tissue, beginning with regenerated skin that grows all layers, glands, and hair STRATEGY 0 « Rapid clinical and market deployment of first launch product SkinTE™ to capture massive wou

  3. Slide 3: Global Regenerative Medicine and Wound Care Markets

    Global Regenerative Medicine and Wound Care Markets ® Current markets remain untapped with redundant Growth in Worldwide Prevalence of products and no autologous (patient’s own tissue/cells) Memes no aoeD tissue engineering ae {| © Complicated skin cancer 20000 Melanoma ® The global market for tissu

  4. Slide 4: The PolarityTE Platform Technology

    The PolarityTE™ Platform Technology Discovered through careful observation of tissue regeneration in real-time, the PolarityTE™ Platform Technology has proved its regenerative capacity in SKIN, bone, muscle, fat, cartilage, nerve, Muscle Lo

  5. Slide 5: Development Pipeline

    Development Pipeline June 2017 > December 2017 >

  6. Slide 6: The PolarityTE Launch Product

    The PolarityTE Launch Prod Using our platform technology, we are able to regenerate full-thickness, fully functional skin. This simple process allows the patient’s own skin to be fully expanded from a small biopsy. The expanded skin regenerates ALL LAYERS (EPIDERMIS & DERMIS), HAIR and APPENDAGES, w

  7. Slide 7: Physiology of Skin and Wound Healing

    Physiology of Skin and Wound Healin Inflammatory phase THREE PHASES OF WOUND HEALING Inflammatory Phase (Days) Immediately following injury and wound creation Vessel contraction, clot formation, control of bleeding Inflammatory mediators and inflammatory cells accumulate and clean wound Proliferativ

  8. Slide 8: Current Therapies

    Current Therapies INTEGRA Integra Bilayer Matrix ~~ a Provides a potential solution for difficult wounds unable to accept a skin graft (exposed bone or tendon) ® Only product routinely used by reconstructive surgeons 2 $300M in revenue, overall Market Cap $3.28B including other surgical devices Sh A

  9. Slide 9: Current Therapies Lack Building Blocks for Regeneration

    for Regeneration Building Bloc Skin Substitute Products Considered in This Report: Therapies Lack t TaN POTEET PINT Matrix MatriStem 1 AlloDerm oflex® Technology Assessment Primat ative Tissue Matrix Primat hronic Wounds Jaloskin Suprathel® Talymed® DressSkin E-Z Derm “orm Dermal Te Animals Cells, A

  10. Slide 10: Current Therapies: Limitations

    Current Therapies: Limitations Oh CAlloDerm ermagraft. Human fibroblast-derived dermal substitute AlloSourceé Ul ’ <> —_ Apligraf add life to healing

  11. Slide 11: Current Therapies: Limitations of Autologous Options

    Current Therapies: Limitations of Autologous Options me " a Epidermis How EPICEL is Made o Old i —~—— Split thickness Dermis Full thickness G Animal Cells

  12. Slide 12: Can Any Current Therapy Regenerate All Layers of Skin?

    Can ANY Current Therapy sige to ONE of UNESEr

  13. Slide 13: The Gold Standard: Split-Thickness Skin Grafts

    The Gold Standard: Split-Thickness Skin Grafts HOW PROBLEMS _ 1. Donor Site Morbidity & Pain Skin ismeshed 2. Stem Cell is Left Behind with Loss of Polarity 7 large wound 3. Contracture and Scarring 4. Non-functional Skin Graft taken from 4 patient's healthy skin > The Follicular Bulge Left Behind H

  14. Slide 14: The REAL Problem: All Tissues Require Polarity

    The REAL Problem All Tissues Require Polarity

  15. Slide 15: Without Polarity Function is Lost

    Without Polarity Function is Lost polarity, the tendency of living organisms or parts to evelop with distinct anterior and posterior (or uppermost ad lowermost) ends, or to grow or orient in a particular irection.

  16. Slide 16: Polarity Drives Hierarchical Tissue Formation

    Polarity Drives Hierarchical Tissue Formation

  17. Slide 17: Polarity

    Polarity Developmen Skin Cells Neuron Pigment of Epidermis of Brain Cell Sperm Egg a Ox = — 7 Ry fave ~—S @) Ai ww dbf : Q Ectoderm Germ (External Layer) Cells Cardiac Muscle Mesoderm (Middle Layer) mr Skeletal Tubule Red Blood Smooth Muscle = Cellofthe Cells Cells Kidney Muscle {in Gut) Endoderm (I

  18. Slide 18: 3 Primary Germ Layers Make All Tissues

    A. Ectoderm 1. Epidermis 2. Brain 3. Glands 4. Keratinous Cell 5. Neuron 6. Spinal Cord 7. Neuron 8. Milk-Secreting Glands 9. Light-Sensing Cells 10. Adrenal Medulla 11. Pigment Cell B. Mesoderm 12. Cartilage Connective Tissue 13. Gonads 14. Cartilage Tissue Cell 15. Striated Muscle Tissue 16. Adren

  19. Slide 19: Skin is Derived from Multiple Germ Layers

    Skin is Derived from Multiple Germ Ectoderm Origin Mesoderm Origin The Interface

  20. Slide 20: Slide 20

  21. Slide 21: Slide 21

  22. Slide 22: Experts Agree with PolarityTE Approach

    Experts Agree with PolarityTE Approac “\Ne are enthusiastic to see the future of this exciting work.” — Michael Longaker on Lough et al. technology EXPERIMENTA DISCUSSION . . a Discussior Transplantation of the LGR6* Epithelial Stem) and LGR6' Stem h the GutDeri Celene Nd for Ret EGR: Epithet Sofeis

  23. Slide 23: The PolarityTE Launch Product

    The PolarityTE Launch Prod Using our platform technology, we are able to regenerate full-thickness, fully functional skin. This simple process allows the patient’s own skin to be fully expanded from a small biopsy. The expanded skin regenerates ALL LAYERS (EPIDERMIS & DERMIS), HAIR and APPENDAGES, w

  24. Slide 24: Stem Cells with a Variety of Vectors for Delivery

    stem with a Variety of Vectors for Delive Final Sort Gate. | wt ” ra £2 D7 EXPERIMENTAL LGR6+ CD34+ Fel GFP | 3= cO3+ ri 7 Transplantation of the LGR6* Epithelial Stem ro et Cell Fluorescence 7 PE-Cy7 Cell into Full-Thickness Cutaneous Wounds = LGR6 £2 Results in Enhanced Healing, Nascent Hair ei)"

  25. Slide 25: Proliferation and Scaffold Imprinting

    Proliferation and Scaffold Imprinting 4 i WAV,

  26. Slide 26: Rapid/Complete Proliferation 48-72 Hours Ex-Vivo

    Rapid/Complete Proliferation 48-72 Hours Ex-Vivo

  27. Slide 27: Fully Functional Regenerated Skin with Hair Growth in a Nude Mouse

    Fully Functional Regenerated Skin with Hair Growth in a Nude Mouse Control LGR6*¢F Day 15 Implant Pocket iy, | LGRE*SFP a) ee A i > ie ee ° as _| a. - Ty ‘4 »* Day 6 © & | ofl 65 Ne: 3 ay ay] Control

  28. Slide 28: Transplantation of a LGR6+ Epithelial Stem Cell-Enriched Scaffold

    Transplantation of a LGR6* Epithelial Stem Cell-Enriched Scaffold for Repair of Full-Thickness Soft Tissue Defects: fitro Development of Polarized Hair Bearing Skin. Lough et al. ‘Activated Cell Sorting 1GR6+/C073+/cD34+ Q2. | Microscopy Bioluminescence Merge Zoom Control 16*GFP Live Cell Ex-Vi Matr

  29. Slide 29: Angiogenesis

    Angiogenesis Relative Fold Expression (A0Ct) Wound Healing EGF/ PDGF Blood Vessel Forming Genes and Protei RELATIVE PROTEIN DENSITOMETRY eo 8 8 BEES Hy 8 TE ee ee wat 2 mee For acibie eer ae ea es — es singe 2 8 rorensell oie ASSES SLESOEIUE TEE SSS EEE oo SE ahead Se reacrautin fl goo g 8 3 500 g F

  30. Slide 30: SEM Validation of Viability and Phenotype

    SEM Validation of Viability and Phenotype Integra DermaMatrix

  31. Slide 31: OO LSPAAD ES MUD Sta DOOODD: B tad

    e ~ OO LSPAAD ES MUD Sta DOOODD: B tad ) = = oe 3 ae tings winos >»

  32. Slide 32: Maintain Viable Bio-reactive Tissue

    Maintain Viable Bio-reactive Tissue |

  33. Slide 33: Development of Functionally Polarized Skin

    Development of Functionally Polarized Skin LGR6 Layered Epithelium Ski nlc Sub-epithelial Mesenchymal Support and Vasculogenesis

  34. Slide 34: Augment Regenerative Healing

    Augment Regenerative Healing ») \I KInT | L Gross Matrix Gross Matrix Healing LGR+ —_ Healing LGR+ The enhanced healing can be seen with the naked eye... Gross Matrix Healing Gross Matrix _ Healing Gross Burn Control e & a

  35. Slide 35: Development of Nascent Hair Follicles

    Development of Nascent Hair Follicles Hair shafts growing through a burn wound ina nude mouse after periwound m@ injection

  36. Slide 36: Safety Data

    Safety Data

  37. Slide 37: What Comes After Skin Regeneration?

    What Comes After Skin Regeneration? FDA Approved Competitor PolarityTE™ Bone Technology Regeneration Technology The PolarityTE™ platform has proved itself in bone, muscle, and nerve regeneration as well

  38. Slide 38: The Holy Grail Of Tissue Regeneration: Blood Vessel Formation

    The Holy Grail Of Tissue Regeneration: Blood Vessel Formation from Capillary bed formation within our bone regeneration construct sprouting surrounding native tissue AND FROM WITHIN our regenerative construct

  39. Slide 39: A Platform Technology with Endless Possibilities

    A Platform Technology with Endless Possibilities . . . @ sexx Ye ® \euralTE vice AdiposeTE

  40. Slide 40: Strategy, Pathway, and Timelines

    Strategy, Pathway, and Timelines Ski Te n Swine Data Human Pilot Trial in Burn Patients Product Registration and Market Entry Mi December 2017 > Manufacturing Optimization] December 2017 > Product Registration and Market Entry January 2018 March 2018 > Manufacturing Optimization

  41. Slide 41: Sales & Financial Projections

    les & Financial Projectio Financial Forecast 2017-2019 ie $30,000 8 g Ea 3 = ‘$25,000 $20,000 vw $300 $15,000 § & 5250 $10,000 $200 $5,000 $150 $100 i=] =] sad B — eso ee ee eee $50 eS ESBEESELT SEES SESLT ELSES SREP SESEESEE SEER EPSRC STIFF SSEPSS ESP TZESR IRS RFS ZFSEEB =| so ——- | ($5,000) _ —=

  42. Slide 42: IP Opportunities

    IP Opportunities ; oogle an : t : | | ute " i genzyMe bo! Epix 4 enn F Astrazeneca? z=

  43. Slide 43: Manufacturing Capabilities

    Manufacturing Capabilities (teal i Ee SCHOOL* MEDICINE Internal Medicine Fully Certified and J Highly Experienced cGTP/cGMP/CLIA Manufacturer Capable of Expanding as PolarityTE™ Grows

  44. Slide 44: Predictable Scalability

    Predictable Scalability he ali Self-Contained GMP Compliant 1 (315) 625-8025 Cell Processing and Production Facilities eww biospherixmedical.com move the incubator to the back and add a microscope chamber ‘add additional processing and incubation modules

  45. Slide 45: Automated Manufacturing

    Automated Manufacturing Automated Manufacturing is being Developed in Parallel to Increase Efficiency, while Decreasing Cost and Variability

  46. Slide 46: The PolarityTEAM - Management

    The PolarityTEAM - Management Denver M. Lough, MD, PhD Chairman, President, CEO, CSO = Inventor/innovator behind patented PolarityTE™ platform = MD/PhD from Georgetown University with Honors = Johns Hopkins Plastic and Reconstructive Surgery Training = Winner of numerous research awards, including b

  47. Slide 47: The PolarityTEAM - Board of Directors

    The PolarityTEAM — Board of Direc Denver Lough, MD, Pl ‘Chairman, Preside Chief Executi 3 q Michael Beeghley, ASA, MPH Jon Mogford, PAD) Director ; Director

  48. Slide 48: The PolarityTEAM - Clinical Board of Advisors

    The PolarityTEAM — Clinical Board of Advisors shannath Merbs, MO, PRO Prof ofOphitholmoloay and Oncology, Wilmer yest, Johns Hopkins Uni, ‘Anand Kumar, MD Ghigf of Plastic Surger Hospital Tiny sata 2. Chrstion Evenson ‘Oncology Depth ol Stephen Milner, MD, DDS/DSc, FRCSE, FACS Director of Clinical B

  49. Slide 49: The PolarityTEAM

    The PolarityTEAM Devin T. Miller, MD Director of Translational Research & Regulatory Strategy = MD from Johns Hopkins University = Over 5 years of translational science research experience in biological chemistry and transplant medicine = Prior Life Sciences Associate at Kairos Ventures evaluating p

  50. Slide 50: Final Human Data Released

    Final Human Data Released Human Proof of Concept Pilot Trial Initiated Product Prelim Human Swine Data Released Data Released Registration & Market Entry First Year in Market Sales of SkinTE™ Projected at $30M Conservatively Targeted Commercial Roll-Out at Limited Market Release (LMR) Burn/Wound Car

  51. Slide 51: Capital Structure

    Capital Structure Converted Options Common Stock Equivalents 7 a Polari tyIE Common Stock Diluted % Preferred Stock —— NAS DAQ: COOL Series A 792,933 4.60% PolarityTE.com Series B 801,820 4.65% Series C 410,247 2.38% Series D 157,776 0.92% Series E 7,050,000 40.91% Common Stock 4,976,768 28.88% ul S

  52. Slide 52: Investment Summary

    Investment Summary ale = a a —e - NN, eh An early stage preclinical regenerative medicine company with every attractive value inflection point still on the table: preclinical data, human proof of concept pilot trials, market entry, initial revenue generation, and commercial scale-up The proprietary

  53. Slide 53: PolarityTE: Welcome to the Shift

  54. Slide 54: Thank You

    Thank You The PolarityTE™ TEAM PolarityTE™, Inc. NASDAQ: COOL www.PolarityTE.com ParadigmShift@PolarityTE.com

PolarityTE — Investor Presentation (March 2017) on 6ix